2001
DOI: 10.1200/jco.2001.19.5.1395
|View full text |Cite
|
Sign up to set email alerts
|

Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

Abstract: ASCT achieves long-term disease-free survival in HD patients. Disease status before ASCT is the most important prognostic factor for final outcome; thus, transplantation should be considered in early stages of the disease. TBI must be avoided in the conditioning regimen because of a significantly higher rate of late complications, including secondary malignancies.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

10
147
2
8

Year Published

2003
2003
2017
2017

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 223 publications
(167 citation statements)
references
References 43 publications
10
147
2
8
Order By: Relevance
“…In our study, 3y OS was 70% in all patients who underwent autologous HSCT (Fig. 1A), and was comparable to that in previous studies [4,12,13]. In addition, OS was favorable even in patients who underwent autologous HSCT in the disease status other than CR, although the disease status was associated with OS, which was similar to the results in many other studies [4,12,13].…”
Section: Discussionsupporting
confidence: 91%
See 1 more Smart Citation
“…In our study, 3y OS was 70% in all patients who underwent autologous HSCT (Fig. 1A), and was comparable to that in previous studies [4,12,13]. In addition, OS was favorable even in patients who underwent autologous HSCT in the disease status other than CR, although the disease status was associated with OS, which was similar to the results in many other studies [4,12,13].…”
Section: Discussionsupporting
confidence: 91%
“…This study was planned by the Adult Lymphoma Working Group of JSHCT, and was approved by the data management committee of TRUMP and by the institutional review board of Nagoya University School of Medicine. 12 Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan; 13 Department of Hematopoietic Stem Cell Transplantation Data Management and Biostatistics, Nagoya University School of Medicine, Nagoya, Japan; 14 Cancer Center, Shimane University Hospital, Shimane, Japan Statistical considerations. Differences between groups were examined using Fisher's exact test for categorical variables.…”
Section: Methodsmentioning
confidence: 99%
“…41,62 Pre-HCT radiotherapy has been shown to be an adverse risk factor for SN. 59,60,62 Among 133 patients with aplastic anemia undergoing allogeneic HCT, pre-HCT immunosuppressive therapy with cyclosporine (a group 1 carcinogen according to the International Agency for Research on Cancer) 124 was associated with five-fold higher rates of SN. 75 …”
Section: Disease- and Transplant-related Risk Factorsmentioning
confidence: 99%
“…The data suggest an interaction with age, with higher risk of SN in younger recipients exposed to TBI compared with older patients. 39,125 However, the role of TBI in SN risk remains unresolved, with six publications providing strong evidence of increased SN risk from TBI exposure, 16,17,32,46,49,60 and eight studies failing to identify an association between TBI and SN. 22,24,33,37,38,41,59,69 …”
Section: Disease- and Transplant-related Risk Factorsmentioning
confidence: 99%
“…The treatment of refractory or relapsed disease has been investigated extensively and high-dose chemotherapy (HDCT) with autologous stem cell support has become the standard protocol in patients with chemo-sensitive disease after induction therapy. Indeed, several nonrandomized studies [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] have suggested a better outcome for patients receiving HDCT. These results have been confirmed by two randomized studies [18,19] comparing a single course of HDCT to conventional chemotherapy in chemo-sensitive patients.…”
Section: Introductionmentioning
confidence: 99%